Substituted-Quinoxaline-Type Bridged-Piperidine Compounds as ORL-1 Modulators
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 5 of these applications claim priority to application PCT/IB2009/006356, filed Jul 20, 2009. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 8,476,271 | Substituted-Quinoxaline-Type Bridged-Piperidine Compounds as ORL-1 Modulators In force · High confidence | Purdue Pharma L.P. | In force | High confidence | ||
| US 9,145,408 | Substituted-Quinoxaline-Type Bridged-Piperidine Compounds as ORL-1 Modulators In force · Medium confidence | Purdue Pharma L.P. | In force | Medium confidence | ||
| US 9,890,164 | Substituted-Quinoxaline-Type Bridged-Piperidine Compounds as ORL-1 Modulators In force · Medium confidence | Purdue Pharma L.P. | In force | Medium confidence | ||
| US 10,519,156 | 9'-AZA[3,9'-BI(BICYCLO[3.3.1]NONAN)]-3'-ONE and Preparation Thereof In force · Medium confidence | Purdue Pharma L.P. | In force | Medium confidence | ||
| US 11,111,246 | Pharmaceutical Salts of Substituted-Quinoxaline-Type Bridged-Piperidine Compounds In force · Medium confidence | Purdue Pharma L.P. | In force | Medium confidence | ||
| Application 15/878,142 | Substituted-Quinoxaline-Type Bridged-Piperidine Compounds and the Uses Thereof Abandoned Abandoned Apr 16, 2019 | Purdue Pharma L.P. | Abandoned | Abandoned Apr 16, 2019 |
6 of 6 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
5 of these are in force and held by Purdue Pharma L.P..
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.